INTRODUCTION: Recent studies for the characterization of the lung cancer genome have suggested that Kras gene was frequently amplified and correlated with activating mutations of Kras, which occur in approximately 5 to 10% of Japanese lung cancers. METHODS: We analyzed Kras mutation and Kras copy number in 172 Japanese non-small cell lung cancer (NSCLC) cases and their relation to the survival of patients. We also studied using fluorescence in situ hybridization to provide direct evidence of Kras amplification in 40 clinical specimens. RESULTS: In 172 NSCLC cases, increased Kras copy number existed in 19 (11.0%) cases. Increased Kras gene copy number was correlated with Kras mutation. Nevertheless, Kras gene copy number gain was not correlated with gender, pathological subtypes, stages, and smoking status. Increased Kras copy number was not associated with overall survival in these 172 cases; however, patients with increased Kras copy number and Kras mutant had significantly worse prognosis, when compared with patients with Kras wild type and Kras not increased. From the fluorescence in situ hybridization analysis, Kras polysomy or amplified patients showed significantly worse prognosis, when compared with Kras disomy patients. CONCLUSION: Kras mutation plus increased copy number was a predictor of poor clinical outcome in patients with NSCLC.
INTRODUCTION: Recent studies for the characterization of the lung cancer genome have suggested that Kras gene was frequently amplified and correlated with activating mutations of Kras, which occur in approximately 5 to 10% of Japanese lung cancers. METHODS: We analyzed Kras mutation and Kras copy number in 172 Japanese non-small cell lung cancer (NSCLC) cases and their relation to the survival of patients. We also studied using fluorescence in situ hybridization to provide direct evidence of Kras amplification in 40 clinical specimens. RESULTS: In 172 NSCLC cases, increased Kras copy number existed in 19 (11.0%) cases. Increased Kras gene copy number was correlated with Kras mutation. Nevertheless, Kras gene copy number gain was not correlated with gender, pathological subtypes, stages, and smoking status. Increased Kras copy number was not associated with overall survival in these 172 cases; however, patients with increased Kras copy number and Kras mutant had significantly worse prognosis, when compared with patients with Kras wild type and Kras not increased. From the fluorescence in situ hybridization analysis, Kras polysomy or amplified patients showed significantly worse prognosis, when compared with Kras disomypatients. CONCLUSION:Kras mutation plus increased copy number was a predictor of poor clinical outcome in patients with NSCLC.
Authors: Junichi Soh; Shinichi Toyooka; Keitaro Matsuo; Hiromasa Yamamoto; Ignacio I Wistuba; Stephen Lam; Kwun M Fong; Adi F Gazdar; Shinichiro Miyoshi Journal: Oncol Lett Date: 2015-06-23 Impact factor: 2.967
Authors: Liza C Villaruz; Mark A Socinski; Diana E Cunningham; Simion I Chiosea; Timothy F Burns; Jill M Siegfried; Sanja Dacic Journal: Cancer Date: 2013-03-22 Impact factor: 6.860
Authors: Caroline E McCoach; Anh T Le; Katherine Gowan; Kenneth Jones; Laura Schubert; Andrea Doak; Adriana Estrada-Bernal; Kurtis D Davies; Daniel T Merrick; Paul A Bunn; W Tom Purcell; Rafal Dziadziuszko; Marileila Varella-Garcia; Dara L Aisner; D Ross Camidge; Robert C Doebele Journal: Clin Cancer Res Date: 2018-04-10 Impact factor: 12.531
Authors: E Birkeland; E Wik; S Mjøs; E A Hoivik; J Trovik; H M J Werner; K Kusonmano; K Petersen; M B Raeder; F Holst; A M Øyan; K-H Kalland; L A Akslen; R Simon; C Krakstad; H B Salvesen Journal: Br J Cancer Date: 2012-10-25 Impact factor: 7.640